statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Havells India, for instance, saw a breakout of its falling resistance trendline adjoining the highs of March 2 and April 8, and formed a big bullish candlestick pattern on the daily timeframe with healthy volumes.

Trade Spotlight | Your play for Biocon, Havells India, Engineers India today

Under the agreement, Biocon will handle the development, manufacturing, and supply of the diabetes management drug, while Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market

Biocon inks licensing pact with Biomm for diabetes management drug Semaglutide in Brazil

Net Sales are expected to increase by 3.5 percent Y-o-Y (down 1.2 percent Q-o-Q) to Rs 3,730.4 crore, according to ICICI Securities.

Biocon Q4 PAT may dip 192.8% YoY to Rs 67.1 cr: ICICI Securities

The Bengaluru-based firm has scored an early win among its peers with the UK approval for the first generic version of liraglutide injectible, which is losing patent protection in November.

Biocon leads India push into weight loss drugs as patents lapse

As part of the deal over 430 employees associated with the business are expected to transition to Eris

Biocon Biologics  signs 10-year supply deal with Eris Lifesciences for Rs 1242 crore

Biocon Share Price | In an another development, the company's subsidiary received observations from US Food and Drug Administration (USFDA).

Biocon shares gain on licence deal with Janssen, J&amp;J for US markets

The trigger for this inspection was a Pre-Approval Supplement (PAS) filed by BBL's customer late last year

US FDA issues 4 observations for Biocon Biologics' insulin facility

Around 70% of stocks in Nifty MidCap 100 and Nifty SmallCap 100 indices witnessed a rise in mutual fund stakes in December 2023 quarter, according to Ace Equities data.

MFs raise stakes in 70% Nifty smallcap, midcap stocks in Q3, despite caution

Ipca Laboratories saw a breakout of downward sloping resistance trendline adjoining highs of December 5 last year and January 12 this year. The stock formed strong bullish candlestick pattern on the daily charts with healthy volumes.

Trade Spotlight | How to trade in HDFC Life, Biocon, Ipca Labs today

Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 332 in its research report dated January 17, 2024.

Buy Biocon; target of Rs 332: Sharekhan

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. It operates through the following segments: Small Molecules, Biologics, Branded Formulations, and Research Services. The Small Molecules segment manufactures spanning statins, immunosuppressants, antifungals, anti-obesity, anti-diabetics, ophthalmologicals, oncologicals, and urologicals etc. The Biologics segment provides Insulins and Analogs, biosimilar Monoclonal Antibodies (MAbs), and recombinant proteins The Branded Formulation segment consists of therapeutic areas of diabetology, oncology, immunology and critical care. The Research Services segment covers Syngene development platforms. The company was founded by Kiran Mazumdar-Shaw on November 29, 1978 and is headquartered in Bangalore, India.

Watchers	429
52-Wk Low	217.50
52-Wk High	315.00

Volume	9.54M
52-Wk High	315.00
52-Wk Low	217.50

Current Price	303.80
Prev Close	299.50
Open	302.00
Dividend Yield	0.73%
50-Day Moving Average	275.23
Beta	0.00
Avg. Volume	9.26M
PE Ratio	29.87

52-Week High	315.00
52-Week Low	217.50
Market Capitalization	358.56B
EPS	10.00
Price to Book	1.82
Revenue Per Employee	8.83M
Enterprise Value/EBITDA	14.26

BIOCON.NSE Biocon

About

Feed

News

Sentiment

Fundamentals